Leading Biotechnology Analyst Geoffrey Porges Joins LEERINK Partners

BOSTON--(BUSINESS WIRE)--LEERINK Partners, a leading healthcare investment bank, announced that Geoffrey Porges has joined its Equity Research team as a Managing Director, Senior Biotechnology Analyst, and Director of Therapeutics Research. Dr. Porges will lead LEERINK's sector coverage of large cap biotechnology stocks and provide coverage for selected established and emerging biopharmaceutical companies. Dr. Porges will be based in the firm's New York office.

"In today's fast-changing biotechnology sector, I'm confident that Geoff's deep regulatory, clinical and market knowledge will add distinct and compelling value."
Dr. Porges brings to LEERINK over 20 years of experience and expertise in executive and investment roles in the biopharmaceutical industry. After establishing Sanford C. Bernstein's biotechnology research coverage in 2003, Dr. Porges has consistently ranked as one of Wall Street's top biotech analysts in Institutional Investor magazine's annual survey. He is a frequent media contributor regarding investment opportunities, and risks, in the biopharmaceutical sector. Prior to joining Bernstein, Dr. Porges served in senior leadership roles at BTG PLC and in the vaccine division at Merck & Co. Before entering the industry, Dr. Porges attended medical school at the University of Sydney and trained in pediatric and internal medicine. He is also a graduate of Harvard Business School.

"Geoff is a phenomenal addition to our leading research franchise and a strong fit with LEERINK's leadership in biotechnology," said Jeff Leerink, Chairman and CEO of LEERINK Partners. "His arrival underscores our ongoing commitment to providing our clients with highly differentiated healthcare insights and best in class biotechnology research."

"We are pleased to welcome a biotech analyst of Geoff's high caliber to LEERINK Partners' Equity Research team," said John L. Sullivan, Senior Managing Director, Director of Equity Research. "In today's fast-changing biotechnology sector, I'm confident that Geoff's deep regulatory, clinical and market knowledge will add distinct and compelling value."

"I am very excited to join LEERINK Partners and look forward to delivering investors both detailed coverage of leading biotechnology companies as well as an integrated view of investment opportunities and risks in the broad biopharmaceutical industry," said Dr. Porges. "Markets, products and geographies are converging in biopharma. Traditional silos separating industry groups have become obsolete, creating new opportunities for innovators and investors alike. With its breadth of coverage, knowledge-led platform, and strong industry and investor relationships, LEERINK is superbly positioned to identify these opportunities for its clients."

About LEERINK Partners

LEERINK Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. LEERINK Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com.

Contacts

LEERINK Partners
Marissa Evans, 617-918-4030
or
Sard Verbinnen & Co
Chris Kittredge/Patrick Scanlan
212-687-8080
 

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.